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A technique for transperineal high-dose-rate (HDR) prostate
brachytherapy and needle biopsy in a standard 1.5 T MRI scan-
ner is demonstrated. In each of eight procedures (in four pa-
tients with intermediate to high risk localized prostate cancer),
four MRI-guided transperineal prostate biopsies were obtained
followed by placement of 14–15 hollow transperineal catheters
for HDR brachytherapy. Mean needle-placement accuracy was
2.1 mm, 95% of needle-placement errors were less than
4.0 mm, and the maximum needle-placement error was 4.4 mm.
In addition to guiding the placement of biopsy needles and
brachytherapy catheters, MR images were also used for
brachytherapy treatment planning and optimization. Because
1.5 T MR images are directly acquired during the interventional
procedure, dependence on deformable registration is reduced
and online image quality is maximized. Magn Reson Med 52:
683–687, 2004. Published 2004 Wiley-Liss, Inc.†
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Prostate cancer, with a projected incidence of 220,900 new
cases in 2003, is the most commonly diagnosed nonskin
cancer in men in the United States (1). Currently, the three
most common treatment alternatives for the management
of localized prostate cancer are watchful waiting, radical
prostatectomy, and radiation therapy. While the first
method minimizes treatment-related morbidity, overly
conservative management has been associated with poor
outcomes (2). While the latter two options offer a good
chance of cure, they can cause significant morbidity, in-
cluding proctitis, incontinence, and erectile dysfunction
(3). Therefore, new techniques that can improve the prog-
nostic accuracy of our current diagnostic methods and
reduce the morbidity of treatment are warranted.
Both of these goals can be addressed using MRI. Because
of its excellent soft-tissue contrast, MRI has great potential
to provide accurate image guidance for low-morbidity per-
cutaneous procedures (4). Compared with ultrasound, the
most commonly used modality to guide needle placement
in the prostate, MRI provides far better visualization of the
prostate and surrounding anatomy (4). More important,
the advent of molecular imaging promises to improve the
diagnostic and prognostic accuracy of imaging by yielding
information based on the molecular and metabolic profiles
of the tissue (5).
Prior work on MRI-guided prostate interventions has
been performed using low-field-strength (e.g., 0.2 or 0.5 T)
open-scanner architectures (6,7). While “open” scanners
offer improved patient accessibility, they do not provide
the highest quality MR images. In an effort to improve
image quality while maintaining patient accessibility,
some groups have investigated hybrid approaches in
which previously acquired 1.5 T MR images were regis-
tered with images acquired in the low-field-strength inter-
ventional scanner (8–10). Other groups have registered
intraoperative ultrasound images with previously ac-
quired 1.5 T MR images (11,12). While both of these ap-
proaches simplify the interventional procedure itself, de-
formable registration between image sets can introduce
inaccuracies, particularly in highly deformable tissues
such as the prostate.
Here, we present a technique for performing MRI-guided
high-dose-rate (HDR) prostate brachytherapy and tissue
biopsy within a “closed” 1.5 T scanner architecture. In a
series of eight treatments in four patients with prostate
cancer, this technique served two purposes. First, it al-
lowed for the acquisition of tissue—for molecular and
histological analysis—from specific sites within the pros-
tate that were accurately registered with the MR image
data. Second, it provided accurate MR image-guided
placement of brachytherapy treatment catheters. In con-
trast to previous work, we performed these interventions
in a standard 1.5 T cylindrical-scanner platform in order to
maximize image quality (through higher field strength,




An MRI-compatible system for planning and execution of
transperineal needle insertion consisting of a lockable po-
1Department of Biomedical Engineering, Johns Hopkins University School of
Medicine, Baltimore, Maryland.
2Radiation Oncology Branch – NCI, National Institutes of Health, DHHS,
Bethesda, Maryland.
3Department of Radiology – Clinical Center, National Institutes of Health,
DHHS, Bethesda, Maryland.
4Laboratory of Cardiac Energetics – NHLBI, National Institutes of Health,
DHHS, Bethesda, Maryland.
5Department of Radiation Oncology, William Beaumont Hospital, Royal Oak,
Michigan.
6Department of Radiology, Johns Hopkins University School of Medicine,
Baltimore, Maryland.
7Department of Electrical and Electronics Engineering, Bilkent University,
Ankara, Turkey.
Grant sponsor: US Army; Grant number: PC 10029 Grant sponsors: NSF
(Engineering Research Center PER grant), NIH training grant (to R.S.), ASTRO
fellowship (to C.M.).
*Correspondence to: Cynthia Ménard, M.D., Radiation Oncology Branch,
National Cancer Institute, National Institutes of Health, Building 10, Rm
B3B69, 9000 Rockville Pike, Bethesda, MD 20892. E-mail:
menardc@mail.nih.gov
Received 12 November 2003; revised 2 February 2004; accepted 17 February
2004.
DOI 10.1002/mrm.20138
Published online in Wiley InterScience (www.interscience.wiley.com).
Magnetic Resonance in Medicine 52:683–687 (2004)
Published 2004 Wiley-Liss, Inc. † This article is a US Government
work and, as such, is in the public domain in the United States of America.
683
sitioning arm (Siemens Medical Systems, Erlangen, Ger-
many), an endorectal imaging coil (USA Instruments, Au-
rora, OH), and a custom-built perineal template was de-
veloped for this application (Fig. 1a). The patient was
placed in the left lateral decubitus position to maximize
perineal exposure in the 1.5 T MR scanner bore (Siemens
Sonata, Siemens Medical Systems).
A 3D-SSFP image volume was acquired (with slices
approximately coplanar with the needle template face) to
register the 3D position of the needle-guiding template
relative to the MR image volume (TR  4.4 ms, TE 
2.2 ms, FA  56°, pixel BW  560 Hz, FOV  25 cm, slice
thickness (ST)  3 mm, 256  256, 60 slices, NEX  1,
scan time  1:20). Prior to positioning, the holes in the
needle template were filled with a water-soluble surgical
lubricant (Surgilube, Fougera, Melville NY) that both eases
catheter insertion and produces strong MR signal (T1 
1850 msec and T2  240 msec, measured using FSE and SE
pulse sequences, respectively). The regular pattern and
spacing of the grid holes were easily recognized in the MR
images (Fig. 1b). Using a custom-written image visualiza-
tion and targeting program (running on a PC networked to
the MR scanner), two points are selected to define an
x-axis direction, two points to define a y-axis direction,
and one point to define the origin of the needle template
coordinate system (the middle hole at the exposed face of
the template). While defining an origin, an x-axis direc-
tion, and a y-axis direction is sufficient to fully constrain
the grid coordinate system, significant inaccuracies can be
introduced because of angulation errors in the slice-select
direction. Therefore, a 0.125“ diameter 6 cm long plastic
tube was fixed to the anterior surface of the endorectal coil
and filled with Surgilube such that it was MR-visible.
Because the grid was rigidly fixed at a 90° angle relative to
the endorectal coil, the path of the endorectal coil accu-
rately defined the insertion axis of the template coordinate
system (the x- and y-axis definitions were automatically
updated such that they were normal to the insertion axis).
After the grid was fully registered, the trajectory of each
needle hole was extended through the MR image space
and superimposed on the image as a colored dot (i.e., each
grid hole is projected along the insertion-axis of the tem-
plate coordinate system). During the procedure, both the
MR scanner and the PC running the image display and
targeting program were controlled from within the scanner
room, the former via an in-room display and mouse (Sie-
mens Medical Systems) and the latter via a cordless mouse
and keyboard (Cordless Elite Duo, Logitech, Fremont, CA).
The targeting display was projected (LP340b LCD Projec-
tor, Infocus, Wilsonville, OR) onto a wall-mounted screen
(Da-Mat, Da-Lite, Warsaw, IN) in the scanner room.
Clinical Procedures
After providing informed consent, patients were enrolled
in an investigational protocol reviewed and approved by
the NIH Clinical Center Institutional Review Board. All
patients were being treated for intermediate to high risk
localized prostate cancer at the Radiation Oncology
Branch of the NCI, NIH Clinical Center. Each of the four
patients underwent MRI-guided biopsy and conformal
HDR brachytherapy boosts at the beginning and end of a
5-week course of conformal external beam radiation ther-
apy.
HDR prostate brachytherapy uses an Iridium-192 source
that is temporarily placed inside the prostate via hollow
closed-tip catheters that are inserted through the perineum
and into the prostate gland, commonly under ultrasound
guidance (13). After parallel and equidistant placement of
14–18 catheters, a set of axial images is loaded into a
brachytherapy dosimetry planning system and the loca-
tion of the prostate, rectum, bladder, and urethra are de-
fined. The system then optimizes the radiation dose to the
prostate while minimizing the exposure of nearby normal
tissues and produces a treatment prescription that defines
the duration for which the radiation source should dwell
at each axial position in each catheter (total radiation time
is 20 min). This treatment, as performed under MRI
guidance, is similar, with the exception that all planning
and placement of catheters were performed within the
MRI scanner.
All procedures were performed under general anesthe-
sia. After registration of the perineal grid (as described
previously), biopsy sites were selected, a grid hole and
insertion depth for each site were read from the targeting
application, the patient table was withdrawn from the
scanner, and MR-compatible 14-gauge single-action bev-
eled biopsy needles were inserted (MRI Devices, Wauke-
sha WI). The patient was then advanced back into the
scanner and, prior to tissue collection, FSE images were
acquired to verify placement of the needles (TR  741 ms,
TE  60 ms, ETL  7, pixel BW  125 Hz/pixel, FOV 
25 cm, ST  4 mm, 256  256, 12 slices, NEX  1, scan
time  0:28).
FIG. 1. Needle placement and imaging device. a: The needle-guid-
ing template is fixed at a right angle to the endorectal imaging coil.
After positioning, both are fixed in place with an immobilization arm.
b: The template holes, filled with surgical lubricant, are easily visu-
alized in MR images. c: After registration of the position and orien-
tation of the needle-guiding template, colored dots (representing
the path of each needle hole) are projected through the image
volume. Visualization of the template allows for easy verification of
this registration.
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Following biopsy collection, needle insertion for HDR
brachytherapy was performed. Generally, two to four 14-
gauge, MR-compatible beveled or straight-tipped guiding
needles (MRI Devices) were inserted at a time, after which
FSE image volumes were acquired to confirm needle
placement. Plastic brachytherapy catheters (5 Fr; Progu-
ide, Nucletron, Columbia, MD) were then inserted through
each guiding needle, which was subsequently removed.
Catheter depths were chosen such that the entire superior–
inferior dimension of the prostate was traversed without
puncturing the bladder wall (which lies immediately su-
perior to the prostate).
After placement of all brachytherapy catheters, a final
set of T2-weighted images (in the axial, sagittal, and coro-
nal image planes) were acquired (TR  3500 ms, TE  121
ms, ETL  9, pixel BW  130 Hz/pixel, FOV  20 cm,
ST  3 mm, 256  256, 26 slices, NEX  2, scan time 
3:38). The images were forwarded to a brachytherapy do-
simetry planning system (PLATO, Nucletron) while the
patient was transferred—without moving the needle tem-
plate or the catheters—to a shielded room for radiation
delivery. Currently, the procedure requires 2 hr for MR
scanning and 5 hr for the entire treatment (from patient
induction to the end of radiation treatment).
RESULTS
Needle Placement Accuracy
In a series of eight procedures in four patients, this system
was used to perform a total of 32 targeted biopsy needle
placements within the prostate. The mean biopsy needle
placement error was 2.1 mm, 95% of the needle placement
errors were less than 4.0 mm, and the maximum error
measured was 4.4 mm (Fig. 2). Needle placement error is
measured as the distance between the intended target site
(i.e., the projection of the needle template hole) and the
middle of the signal void created by the biopsy needle. As
axial images were acquired and control of insertion depth
is very accurate, only errors in the transverse plane were
measured. Moreover, because biopsy cores are 1.0 cm long
but only 1.5 mm in diameter, a transverse error in needle
placement is much more significant than insertion depth
error.
High-Dose-Rate Brachytherapy Catheter Placement
Following acquisition of four tissue samples in each pa-
tient, 14–15 HDR brachytherapy catheters were placed
within the prostate. Total MR-time for placement of the
catheters in the first two treatments was 2 hr; catheter
placement required 1.5 hr in the subsequent six treat-
ments. Figure 3 shows catheter placements for HDR
brachytherapy treatments delivered before (Fig. 3a) and
after (Fig. 3b) a 5-week course of external beam radiation
therapy. Characteristic changes induced by radiation treat-
ment (namely, atrophy of the normally bright peripheral
zone of the prostate) are clearly visible in the second
treatment. Figure 3c,d shows radiation isodose contours
for each radiation treatment along with contours outlining
the prostate, urethra, and the rectum. While the contour
maps in Fig. 3 only show dose distribution in 2D, the
treatment plan is generated and optimized in 3D using a
full volume of MR data. A 3D measure of dose delivery to
the prostate, V100 (percent of the target receiving 100%
of the prescribed dose), was consistently greater than 90%,
while a 3D measure of urethral overdose, urethral V125
FIG. 3. High-dose-rate (HDR) brachytherapy catheter placement
and isodose maps. At the beginning (a) and end (b) of a 5-week
course of external beam radiation therapy, HDR brachytherapy was
performed using catheters placed under MRI guidance (both im-
ages are from the same patient). c,d: Radiation isodose maps,
corresponding to a,b, indicate 150% (red contour), 125% (orange
contour), 100% (green contour), and 75% (blue contour) of the
prescribed radiation dose (1050 cGy). The prostate (gray filled re-
gion), urethra (white region inside the prostate), and rectum
(hatched region) are also shown. Note that the green, 100% dose
contour conforms well to the prostate margin, while overdose of the
urethra and rectum is avoided.
FIG. 2. Needle placement accuracy histogram and maximum-like-
lihood Rayleigh distribution. Needle location errors (distance, mea-
sured in the axial plane, between the needle void and the intended
target site) for the 32 biopsy needle placements. The mean place-
ment error was 2.1 mm (error distribution is modeled by a Rayleigh
distribution with a sigma value of 1.6 mm).
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(percent of the urethra receiving 125% of the dose) was
5%.
DISCUSSION
Conventional MR imaging, MR spectroscopic imaging, dy-
namic contrast-enhanced MRI, and diffusion-weighted
MRI have all shown great potential for the diagnosis and
assessment of prostate cancer. However, there has been a
significant barrier between the collection of these data and
its application for targeted tissue acquisition and therapy.
It has been widely assumed that the standard architecture
of high-field MRI scanners precludes percutaneous access
to the prostate. Therefore, most work has focused on the
deformable registration of images acquired in high-field
scanners (which contain valuable anatomical and func-
tional data) with images acquired via ultrasound, CT, or
low-field open MRI (which are more amenable to image-
guided interventions). This deformable registration step
from MRI to CT or ultrasound has been considered the sine
qua non for these procedures (14). Here, we have shown
that transperineal needle placement for brachytherapy and
tissue biopsy can be effectively performed inside a stan-
dard 1.5 T MRI scanner with a 60-cm bore.
As this is a clinical procedure in which the patient is
under general anesthesia, we placed great emphasis on
choosing a very robust and simple registration technique.
While point-based registration techniques have greater
precedence in the literature and allow for assessment of
registration accuracy (15), we found that unambiguous and
rapid localization of single points (i.e., 3 mm diameter
glass spheres filled with gadolinium solution) using MRI
to be problematic and subject to frequent failure. There-
fore, we chose a registration method that relies on more
easily recognized patterns (e.g., the gel-filled perineal grid
and the long gel-filled tube on the endorectal coil) to
increase reliability. With this registration technique, the
dominant source of needle placement error appears to be
needle deflection within the tissue. In development stud-
ies using soft homogeneous gel phantoms (which do not
cause appreciable needle deflection), needle placement
errors were consistently under 2 mm. In addition, the
distribution of needle placement errors (Fig. 2) is accu-
rately modeled using a Rayleigh distribution, which as-
sumes that error has an independent and identical normal
distribution in the x- and y-dimensions with no direc-
tional bias. This is the expected error distribution if needle
deflection, and not some systematic error source, was re-
sponsible for the observed errors.
The ability to perform needle placement in a standard
MR scanner architecture has several important applica-
tions. Primarily, it will allow for the acquisition of tissue
biopsies that are accurately colocalized with 1.5 T MR
data. Thus, this method provides an ideal platform for the
histologic validation of various MR imaging techniques.
Prior methods have relied on correlations with tissue bi-
opsy obtained under ultrasound guidance or with de-
formed whole gland specimens (16), both of which intro-
duce significant localization errors. Second, because MRI
provides excellent visualization of both the intra- and
periprostatic anatomy, this technique will allow for serial
acquisition of tissue from a specified site within the pros-
tate. With techniques such as transrectal ultrasound guid-
ance, it is much more difficult to obtain tissue consistently
from the same site within the gland. Serial tissue acquisi-
tion will be crucial for the development of prostate cancer
therapeutics (i.e., a tumor can be serially biopsied during
the course of treatment to study the therapeutic agent’s
effect on the molecular and histological profile of the tis-
sue) (17). Finally, this technique provides for direct plan-
ning and execution of a minimally invasive therapeutic
procedure based on high-quality MR images. In previous
work in animal models (in a standard 1.5 T scanner), we
have demonstrated MRI guidance and monitoring while
delivering solid and liquid therapeutic agents to the pros-
tate (18).
In conclusion, a system for percutaneous needle access
to the prostate inside a standard 1.5 T MRI scanner has
been developed and applied in eight clinical procedures.
Despite the relatively small bore size (60 cm) of the scan-
ner, access to the perineum is possible by placing the
patient in the left lateral decubitus position. Subsequent
work will explore applications of this technique using
dynamic contrast enhancement, MR spectroscopic imag-
ing, and diffusion-weighted imaging.
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